Sign in
CompletedPhase 1

Non-invasive Vagal Nerve Stimulation in Alcohol Use Disorder

Key facts

Who runs it
VA Office of Research and Development
Where
San Diego, United StatesSee the site
Trial code
Status
Completed
Phase
Phase 1
People taking part
19 people enrolled
Started
2 May 2022
Ended
1 May 2024
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Cervical transcutaneous vagus nerve stimulation (active comparator)
  • Cervical transcutaneous vagus nerve stimulation (sham comparator)
Record updated
3 July 2025

Who can take part

Age
21 years to 65 years
Sex
Men only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Veteran
  • Male subjects between 21 and 65 years of age
  • Current DSM-5 diagnosis of AUD with at least one functional disability due to alcohol use, current alcohol craving, and current heavy drinking (>4 drinks on any day or >14 drinks per week)
  • Able to forgo consumption of alcohol for 24 hours without any serious discomfort including nausea/vomiting, visual/auditory/tactile hallucinations, or non-essential tremor

Who cannot take part

  • Evidence of a maladaptive pattern of substance use or abuse other than alcohol one month prior to screening visit
  • Vagus nerve stimulation related criteria: history of carotid endarterectomy, severe carotid artery disease (e.g., history of transient ischemic attack (TIA) or stroke], congestive heart failure, cardiac arrhythmia, known severe coronary artery disease or recent myocardial infarction (within 5 years), history of seizure or syncope (within past year), prior neck surgery
  • Clinical Institute Withdrawal Assessment of Alcohol Scale (CiWA) score >=9 on the day of the scan (symptoms judged to be due to co-existing anxiety or headache disorders will not be counted toward the total)
  • Severe mental illness, e.g., psychosis or bipolar disorder
  • History of neurological disorder that might be associated with cognitive dysfunction
  • History of head trauma involving loss of consciousness >24 hours
  • Clinically significant uncontrolled/unstable medical illness or clinically significant surgery within 1 month of the screening visit
  • MRI-related exclusion criteria: cardiac pacemaker, metal fragments in eyes/skin/body, aortic/aneurysm clips, heart-valve replacement, copper intrauterine device, shunt (ventricular or spinal), neuro/bio-stimulators
  • Currently or recently (within last 90 days) enrolled in abstinence-based treatment program
  • At risk for suicide or homicide

Where in United States

  • VA San Diego Healthcare System, San Diego, CASan Diego, United States

About the trial

What the trial wants to find out

Alcohol use disorder (AUD) is a major health concern amongst Veterans as it causes poor health, lost days at work, impaired psychosocial functioning, and decreased quality of life. Current treatment options for AUD show limited effectiveness, which is exemplified by high relapse rates. Chronic heavy drinking results in psychological and physical distress during abstinence, including anxiety, irritability, and general discomfort, which increases the urge to drink to relieve these symptoms. The hypothesis of this study is that noninvasive vagal nerve stimulation (nVNS) can modify the perception of such inner bodily sensations of distress, and consequently reduces the drive to drink for relief. The aim of this study is to establish feasibility and acceptability of applying nVNS as a rehabilitative treatment for AUD in Veterans. The study will also evaluate the effect of nVNS on functional outcomes, quality of life, distress, and craving, and if nVNS alters neural activation patterns in brain regions involved in the perception and awareness of distress and pain.

The 2 groups in the trial

  • Active cervical transcutaneous vagus nerve stimulationExisting treatment, for comparison

    Participants will be assigned to active transcutaneous vagus nerve stimulation, received once during each of the study visits and self-administered twice a day for a week.

    Treatment: Cervical transcutaneous vagus nerve stimulation (active comparator)

  • Sham cervical transcutaneous vagus nerve stimulationPlacebo, for comparison

    Participants will be assigned to sham transcutaneous vagus nerve stimulation, received once during each of the study visits and self-administered twice a day for a week.

    Treatment: Cervical transcutaneous vagus nerve stimulation (sham comparator)

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Non-invasive Vagal Nerve Stimulation to Improve Functional Outcomes in Veterans With Alcohol Use Disorder
Record updated
3 July 2025